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Available online 5 March 2013Nerve growth factor (NGF), a member of the neurotrophin family, is responsible for the
maintenance and survival of cholinergic neurons in the basal forebrain. The degeneration of
cholinergic neurons and reduced acetycholine levels are hallmarks of Alzheimer's disease (AD)
as well as associated with learning and memory deficits. Thus far, NGF has proven the most
potent neuroprotective molecule against cholinergic neurodegeneration. However, delivery of
this factor into the brain remains difficult. Recent studies have begun to elucidate the potential
use of monocytes as vehicles for therapeutic delivery into the brain. In this study, we employed
different transfection and transduction methods to generate NGF-secreting primary rat
monocytes. Specifically, we compared five methods for generating NGF-secreting monocytes:
(1) cationic lipid-mediated transfection (Effectene and FuGene), (2) classical electroporation,
(3) nucleofection, (4) protein delivery (Bioporter) and (5) lentiviral vectors. Here, we report that
classical transfection methods (lipid-mediated transfection, electroporation, nucleofection) are
inefficient tools for proper gene transfer into primary rat monocytes. We demonstrate that
lentiviral infection and Bioporter can successfully transduce/load primary rat monocytes and
produce effective NGF secretion. Furthermore, our results indicate that NGF is bioactive and that
Bioporter-loaded monocytes do not appear to exhibit any functional disruptions (i.e. in their
ability to differentiate and phagocytose beta-amyloid). Taken together, our results show that
primary monocytes can be effectively loaded or transduced with NGF and provides information
on the most effective method for generating NGF-secreting primary rat monocytes. This study
also provides a basis for further development of primary monocytes as therapeutic delivery
vehicles to the diseased AD brain.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.Keywords:
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NGF1. Introduction
Alzheimer's disease (AD) is a progressive neurodegenera-
tive disease characterized by the deposition of tau-associated
neurofibrillary tangles and β-amyloid (Aβ)-associated senile
plaques, the loss of cholinergic neurons, the emergence ofotherapy, Anichstrasse
12; fax: +43 512 504
Humpel).
 BY-NC-ND license.inflammation and distinct cerebrovascular dysfunctions. Se-
vere cognitive decline and memory deficiencies have been
attributed to the degeneration of cholinergic neurons and the
lack of acetylcholine. Thus, neuroprotective therapies (i.e.
growth factor administration) that counteract this neuronal
loss may prove beneficial in alleviating AD-associated memory
loss and diminished cognition.
NGF is a neurotrophic factor that among other functions
promotes the survival and function of cholinergic neurons in
the basal forebrain. Evidence has shown that NGF stimulates
neuronal cell function, improves cognitive function, and pre-
vents cholinergic neuron cell death. Furthermore, recent
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neurodegenerative phenotype in transgenic mice (Capsoni et
al., 2010). However, the ability to safely and effectively deliver
NGF to the brain has proven difficult. Previous investigations
have explored several strategies to deliver NGF into the brain
including: intracerebroventricular administration (Seiger et al.,
1993), ex vivo gene therapy using grafts of NGF-secreting
fibroblasts (Tuszynski et al., 2005) or cells transfected by an
adeno-associated virus gene transfer (Mandel and Burger,
2004) or a lentiviral vector (Nagahara et al., 2009). These
procedures, however, resulted in adverse side effects from
widespread growth factor distribution as well as required
neurosurgical and invasivemeans to administer NGF. Due to an
ever growing AD disease population such methods may prove
inefficient and costly for therapeutic purposes. Thus, re-
searchers have turned to less invasive methods for NGF
delivery including: Transferrin receptor-mediated transport
(Granholm et al., 1998), intranasal or intraocular application
(Capsoni et al., 2009), poly (butyl cyanoactylate) nanoparticle
(Kurakhmaeva et al., 2009), microsphere (Gu et al., 2009) or
engineered T-cell (Kramer et al., 1995) transport. We have
previously demonstrated that NGF-loaded monocytes trans-
planted into the brain can protect cholinergic neurons against
degeneration (Zassler and Humpel, 2006). More recently, we
showed in proof-of-principle that monocytes can be used as a
carrier system to deliver NGF to the brain (Böttger et al., 2010).
This strategy should not only provide a non-invasive and
simple mode of delivery (via peripheral administration), but
also potentially restrict NGF targeting to lesion sites (avoiding
adverse side effects caused by systemic NGF administration).
Although many methods of gene transfer have been
developed for effective genetic modification of mammalian
cells, the genetic engineering and maintenance of monocytic
cells has proven difficult. In this study, we compared five
methods of generating NGF-secreting primary rat monocytes:
(1) lipid-mediated transfection(EffecteneandGuGene), (2) clas-
sical electroporation, (3) nucleofection, (4) protein delivery
using Bioporter and (5) lentiviral vectors. In this study, we
show that classical transfection methods using electroporation
or lipid-mediated transfection (Effectene and Fugene HD) are
inadequate for proper transfection of primary rat monocytes
with NGF. In addition, we show that nucleofection can transfect
primary rat monocytes, however, with high variability and poor
reproducibility. We report that the transduction of primary rat
monocytes is best achieved by using lentiviral vectors or the
protein delivery system Bioporter. We also demonstrate that
Bioporter does not altermonocyte function asmeasured by their
ability to phagocytose Aβ and begin differentiation.
2. Methods
2.1. Expression vector construction
All non-viral transfection experiments were carried out
using the expression vectors pEF-NGF or pcDNA3.1-NGF.
Expression vector pEF-neo (5636 bp) was generated as pre-
viously described (Wiesenhofer andHumpel, 2000; Zassler and
Humpel, 2006) and contains the functional gene NGF (rat,
[GenBank: M36589], 723 bp) subcloned into a unique EcoRI
restriction site in the pEF-neo vector. pEF-(−) was used
in control experiments and consists of the pEF-neo vectorcontaining a 380 bp Stuffer inserted into a unique BstXI
restriction site. In order to generate pcDNA3.1-NGF, the coding
sequence of rat NGF was amplified from plasmid pEF-NGF
using primers CACCATGTCCATGTTGTTCTAC and TCAGCCT
CTTCTTGCAGC. The PCR fragment was gel-purified and cloned
into mammalian expression vector pcDNA3.1D/V5-His-
TOPO (Invitrogen) at BamHI and XbaI sites. The fidelity
and orientation of pcDNA3.1D/V5-His-ratNGF was then
confirmed by restriction digest and sequencing. The
plasmid pcDNA3.1-ratNGF under the control of the CMV
promoter was generated to determine if transfection
efficiency could be optimized with a different expression
vector and promoter. Two lentiviral vectors (pHR-bA-NGF
and pHR-SFFV) were also generated under the β-actin and
SFFV promoters (see below for details).2.2. Isolation of primary rat monocytes
Primary rat monocytes were freshly isolated as previously
described by us with some modifications (Humpel, 2008;
Böttger et al., 2010; Hohsfield and Humpel, 2010). In brief,
Sprague–Dawley rats (250 g, Himberg, Austria) were anes-
thetized by an intraperitoneal injection of 40 mg/kg body
weight thiopental (Sandoz, Kundl, Austria) and perfused with
500 ml of 4 °C pre-chilled 10 mM phosphate-buffer saline
(PBS)/2.7 mM EDTA/25 mg/ml heparin, pH 7.3 through the
left ventricle. The collected effluent was centrifuged at 550 ×g
for 10 min at 4 °C. The perfusate pellet was resuspended in
50 ml of 10 mM PBS/1% bovine serum albumin (BSA; SERVA
Electroporesis, Heidelberg, Germany)/2.7 mM EDTA, pH 7.3
and carefully overlaid on a Percoll working solution (Scriba
et al., 1996). After centrifugation at 500 ×g for 30 min at 4 °C,
peripheral blood mononuclear cells (PBMC) were harvested
from the interface. PBMC were then washed once with 50 ml
of PBS and ~20 × 106 PBMC were resuspended in 100 μl of
PBS/BSA/EDTA. Monocytes were purified from PBMC by
negative magnetic selection: PBMC were incubated in a cock-
tail consisting of four different purified anti-rat monoclonal
antibodies (20 μg of each: CD8a (clone OX-8), CD5 (clone
OX-19), CD45RA (clone OX-33), PAN T (clone OX-52); all
from Cedarlane Laboratories, Szabo, Austria) for 10 min at
4 °C shaking. PBMC were washed once with PBS and
resuspended in 100 μl of PBS/BSA/EDTA and 40 μl of MACS
Goat Anti-Mouse-IgG Microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany). PBMCwere incubated for 15 min at 4 °C
on a shaker and following incubation washed once with PBS.
The cells were resuspended in 1000 μl of PBS/BSA/EDTA
and then applied to a MS-MACS column fixed to a strong
magnet. The purifiedmonocytes were centrifuged and pooled
for further experiments. Approximately 10 × 106 cells were
isolated from one adult rat. The described isolation proce-
dure yields approximately 90–95% CD68-positive monocytes
(Moser and Humpel, 2007; Böttger et al., 2010). Monocytes
were counted using the Cell Coulter Counter (COULTER®Z™
Series, Fischerlehner & Kucera, Innsbruck, Austria) in a range
from 5.5 to 10 μm. All animal experiments were approved by
the Austrian Ministry of Science and conformed to the
Austrian guidelines on animal welfare and experimentation.
All possible steps were taken toward reducing the number of
animals used and their suffering.
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Freshly isolated monocytes were transiently transfected
with pEF-(−), pmaxGFP, or pEF-NGF plasmids by electropora-
tion using Electroporator BTX 830 (BTX Harvard Apparatus)
according to the manufacturer's recommendations. pmaxGFP
plasmid was provided from Amaxa and used to visualize
transfection efficiency. For optimal cell survival and transfec-
tion efficiency, cells were incubated 5 min on ice with 10 μg of
plasmid DNA and subsequently electroporated with 1 pulse at
500 V for 1 ms. Transfection conditions were optimized for
plasmid DNA concentration, cuvette gap width, pulse length
and pulse number. The effects of different electroporation
buffers (HEPES and PBS), incubation without ice, and an added
10 min recovery period were also evaluated (data not shown).
Control samples were either electroporated using an empty
vector (pEF-(−)) or electroporated without pulse. Following
electroporation, cells were centrifuged at 250 ×g for 5 min,
resuspended in glia (Optimem I, 5% horse serum, 0.5% FCS) or
slice (50% MEM/HEPES (Gibco), 25% heat-inactivated horse
serum (Gibco/Lifetech, Austria), 25% Hanks' solution (Gibco),
2 mM NaHCO3 (Merck, Austria), 6.5 mg/mL glucose (Merck),
and 2 mM glutamine (Merck), pH 7.2) culture medium with-
out antibiotics/antimycotics, plated on pre-warmed 24-well
or 6-well collagen-coated culture plates, and incubated for
1–7 days at 37 °C/5% CO2. After incubation, cell supernatants
were collected for NGF ELISA and/or pooled for addition to
organotypic brain slices or cells were stained for further
microscopic analysis. Primary astrocytes were isolated as
previously done (Wiesenhofer and Humpel, 2000; Zassler et
al., 2005a) and used as a positive control.
2.4. Effectene transfection
Freshly isolated rat monocytes were transiently transfected
with pEF-NGF plasmid using the non-liposomal lipid reagent
Effectene Transfection Reagent (QIAGEN) according to the
manufacturer's instructions. Briefly, 2 × 104–2 × 105 cells
were added to each well in glia culture medium (Optimem I,
5% horse serum, 0.5% FCS) on 24-well collagen-coated culture
plates. Effectene Transfection Reagents were prepared in glia
culture medium (without antibiotics/antimycotics) and added
drop-wise to the cells. The transfection method was optimized
by testing the effects of: the number of cells added, prolonged
incubation time, and removal of complexes after 16 h (data not
shown). Cells were incubated with transfection complexes for
24 h. After incubation, cell supernatants and extracts were
collected for further use. Primary astrocytes were isolated as
previously done (Wiesenhofer andHumpel, 2000; Zassler et al.,
2005a) and used as a positive control.
2.5. FuGENE HD transfection
Primary cultures of freshly isolated rat monocytes were
transiently transfectedwith pEF-NGF plasmid using FuGeneHD
Transfection Reagent (Promega) according to manufacturer's
instructions. Briefly, cells were seeded 1 × 105 cells per well
in medium (without antibiotic/antimycotics). Cells were
incubated at 37 °C until reaching 80% confluency on the day
of transfection. On the day of transfection, the DNA-FuGENE
mixwas prepared in Optimem (Gibco) and added drop-wise tothe cells. Different concentrations of DNA, amount of FuGENE
HD reagent, incubation times with transfection mix, ‘boosting’
with transfection mix, and recovery times were also evaluated
(data not shown). Cells were incubated with transfection
complexes for 24, 48, or 72 h in Amaxa culture medium (10%
FCS, 2 mM glutamine, 1 ng/ml M-CSF, 1 ng/ml GM-CSF). After
incubation, cell supernatants were collected for further use.
2.6. Nucleofection
Primary cultures of freshly isolated rat monocytes were
nucleofected with pEF-(−), pmaxGFP, or pEF-NGF using the
Human Monocyte Nucleofection kit (Amaxa) according to the
manufacturer's instructions. Monocytes were pelleted directly
following isolation at 250 ×g for 5 min. Cell pellets were
resuspended in 110 μl of Nucleofector solution (Amaxa),
mixedwith plasmidDNA, and transferred to anAmaxa cuvette.
Nucleofectionwas performed using the Amaxa programY-001.
Control samples were nucleofected using the empty vector
(pEF-(−)). Immediately following nucleofection, 500 μl of
pre-warmed glia culture medium (Optimem I, 5% horse
serum, 0.5% FCS) (without antibiotics/antimycotics) or Amaxa
culture medium (10% FCS, 2 mM glutamine, 1 ng/ml M-CSF,
1 ng/ml GM-CSF) was added to the cuvette and subsequently
transferred to a collagen-coated 24-well culture plate.
Nucleofected cells were incubated for 1–2 days at 37 °C 5%
CO2. After incubation, cell supernatants and extracts were
collected for NGF ELISA or cells were stained for further
microscopic analysis. Primary astrocytes were isolated as
previously done (Wiesenhofer and Humpel, 2000; Zassler
et al., 2005a) and used as a positive control.
2.7. Lentiviral mediated infection of target cells
The coding sequence of rat NGF was amplified from
plasmid pEF-NGF using primers ON3370 caaaaaagcaggctccg
ccaccatgtccatgttgttctacactctg and ON3371 CAAGAAAGCTGGG
TCT CAGCCTCTTCTTGCAGCCTTC, gel-purified and reamplified
using primers ON1106 GGGGACAAGTTTGTACAAAAAA GCA
GGC Tcc and ON1107 GGGGA CCACTTTGTACAAGAA AGC TGG
GTc to generate attB1 and attB2 sequences, respectively.
The purified PCR product was gel purified and recombined
into pDONR207 using BP clonase (Invitrogen) to generate
pENTR-rNGF. After sequence verification, lentiviral expres-
sion plasmids were generated by recombining pENTR-rNGF
with pHR-SFFV-DEST and pHR-ba-DEST using LR clonase
(Invitrogen). The resulting lentiviral constructs pHR-SFFV-rNGF
and pHR-ba-rNGF express rNGF under the control of the
SFFV and beta actin promoter, respectively. Human embry-
onic kidney cells (HEK293T) were transiently transfected
with pHR-SFFV-rNGF or pHR-ba-rNGF along with psPAX2
packaging and pVSV-G pseudotyping plasmids for 72 h.
Twenty-four hours after transfection, the culture media was
exchanged for the growth media required for rat monocytes
and viral particle containing supernatants harvested 48 and
72 h after transfection. The supernatants were filter steril-
ized, supplemented with 4 μg/ml polybrene and added to
0.5 × 106 rat monocytes seeded into 24-well plates. HeLa
cells were used as a positive control. The vector pHR-
SFFV-Venus-NLS-PEST(VNP) expresses a short-lived nuclear
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effective transduction and/or as a negative control.
2.8. Bioporter protein delivery
Primary cultures of freshly isolated rat monocytes were
loaded with recombinant NGF using the Bioporter Protein
Transfer Reagent (QuickEase). Briefly, two vials of Bioporter
reagent were prepared: 2.5 μl of Bioporter reagent was mixed
with or without (negative control) 100 ng of recombinant NGF
in 100 μl of sterile PBS (pH 7.4) and then incubated with the
reagent for 5 min at 20 °C. Following incubation, 2.5 × 106
monocytes were resuspended in 400 μl Optimem and added to
two vials, each containing diluted Bioporter reagent. The cells
were then incubated for 3 h rotating at 10 rpm (Pluriplex
rotor). After incubation, cells were centrifuged and dissolved in
500 μl of Optimem. The cells were then pooled (5 × 106 cells),
placed into a new eppendorf tube, and washed 3× with
Optimem. After washes, the cell pellet (~5 × 106 cells) was
resuspended in 1.5 ml of pre-warmed Amaxa medium and
cells were cultured on a collagen-coated 6-well plate for 24 h
at 37 °C. Following 24 h incubation, the supernatant was
collected for further use.
2.9. FITC-Aβ phagocytosis and differentiation in Bioporter-loaded
monocytes
Following Bioporter treatment, primary rat monocytes
(~10,000/well) were added to 400 μl culture medium (MEM
+1 mg/ml BSA + 25 mM Hepes, pH = 7.3, ±10 ng/ml rat
macrophage colony-stimulating factor (M-CSF) (Peprotech))
in collagen-coated Lab-Tek chamber glass slides (Nunc) and
incubated for two days at 37 °C/5% CO2. Monocytes were
then washed and exposed to fluorescein isothiocyanate
(FITC)-β-amyloid1-42 peptide (2.5 μg/ml, Bachem) for 2.5 h.
Following incubation with Aβ peptide, cells were washed and
then visualized under the fluorescence microscope (Leica
DMIRB). Images were obtained as described below. Cells
were then fixed with 4% PAF and stained for ED1.
2.10. Functional assay of NGF and cytokine secretion by
Bioporter-loaded monocytes
Following Bioporter treatment, primary rat monocytes
(~ 1 × 106) were incubated in 500 μl of culture medium ±
10 μg rat Aβ1-42 (Calbiochem) at 37 °C/5% CO2. Supernatant
was collected at 0.2, 3 and 24 h. Subsequently, supernatants
were evaluated for NGF and cytokine secretion by ELISA.
2.11. Fluorescence microscopy
To evaluate effective transfection efficiency, following
incubation, pmaxGFP transfected cells were washed with PBS
and then fixed with 4% PFA for 30 min at 4 °C. Following
washes, cellswere stainedwith nuclear DAPI (1:10,000, Sigma)
for 20 min. Cells were then washed with PBS and visualized
under the fluorescence microscope (Leica DMIRB). DAPI and
GFP microscope images were obtained using Improvision
Openlab 4.0.4 imaging software captured with DAPI and FITC
filter sets, respectively.2.12. Flow cytometry
Cell viability was determined by analyzing the number of
necrotic and apoptotic cells by flow cytometry (BD Accuri C6,
BD Biosciences) using annexin V-FITC and propidium iodide
(PI; Annexin V-FITC Apoptosis Detection Kit, BD Biosciences)
staining according to manufacturer's instructions. Gating was
performed on monocytes based on side-scatter and forward-
scatter properties. All necessary controls were included.
2.13. Organotypic brain slices
Cholinergic neurons in organotypic brain sliceswere cultured
as previously described (Weis et al., 2001; Humpel and Weis,
2002; Böttger et al., 2010). Briefly, the basal nucleus of Meynert
of postnatal day 10 (P10) rats was dissected under aseptic
conditions, 400 μm slices were cut with a tissue chopper
(McIlwain, USA), and the slices were placed on a 30-mm
Millicell-CM 0.4 μm pore membrane culture plate inserts (7–8
slices per membrane). Slices were cultured in 6-well plates at
37 °C/5% CO2 with 1.2 ml/well of pooled and filtered medium
containing pEF-NGF or pEF-(−)-transfected cells or slice
medium supplemented with or without 10 ng/ml recombinant
NGF for 2 weeks. We have previously established that 400 μm
brain slices become thinner following 2 weeks of incubation
with a thickness of approximately 100 μm. This flattening is also
an internal control indicating a good preparation and dissection.
Slices that did not flatten were immediately removed from the
experiments.
2.14. Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed (Zassler et al., 2005b; Zassler and Humpel, 2006; Böttger
et al., 2010; Hohsfield andHumpel, 2010). Brain sliceswere fixed
for 3 h at 4 °C in 4%PFA/10 mMPBS,washed in PBS and stored at
4 °C until use. Cultured cells were fixed for 30 min in 4% PFA.
After fixation, slices/cells were washed with 0.1% Triton/PBS
(T-PBS) for 30 min at 20 °C and then pretreated with 5%
methanol/1% H2O2/PBS for 20 min to destroy endogenous
peroxidase. Slices/cells were then washed 3× with PBS and
blocked in 20% horse serum/0.2% BSA/T-PBS for 30 min.
Following blocking, cells and slices were incubated with the
primary antibody against choline acetyltransferase (ChAT, 1:750;
AB144P, Chemicon or Millipore) or ED1 (1:500; Chemicon or
Millipore) in 0.2% BSA/T-PBS overnight and 2 days at 4 °C,
respectively. Slices/cells were then washed and incubated with
secondary anti-goat (ChAT) or anti-mouse (ED1) biotinylated
antibodies (1:200, Vector Laboratories, USA) in 0.2% BSA/T-PBS
for 1 h at 20 °C. After washing, slices/cells were incubated in
avidin–biotin complex solution (ABC; Elite Standard PK6100,
Vector Laboratories) for 1 h at 20 °C. Finally, the cells were
washed 3× with 50 mM Tris-buffered saline (TBS) and then
incubated in 0.5 mg/ml 3,3′ diaminobenzidine (DAB)/0.003%
H2O2/TBS at 20 °C in dark until signal was detected. Once DAB
staining was visible, the reaction was stopped by adding TBS to
cells. Slices/cellswerewashed and then evaluated bymicroscopy
(Leica DMIRB). Alternatively, NGF-positive monocytes were
detected by immunofluorescence using the primary antibody
against NGF (1:250; Cedarlane) and anti-rabbit Alexa 488
secondary antibody (1:400; Invitrogen). Following washes,
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20 min. Fluorescence microscope images were obtained using
Improvision Openlab 4.0.4 imaging software captured with
Alexa488/FITC filter sets. Omission of the primary antibody
served as a negative control. For confocal microscopy, the cells
were visualized with a Leica TCS SP5 microscope under a 64x
glycerol objective and processed with Huygens Deconvolution
and Imaris V6.4 software.
2.15. NGF ELISA
The amount of NGF secreted into the supernatant by
transfected and control cells was determined using an indirect
sandwich enzyme-linked immunosorbent assay (ELISA;
Promega) as previously described (Zassler and Humpel, 2006;
Böttger et al., 2010). Cell supernatants were collected each day
following transfection and assayed for NGF content. Briefly,
96-well ELISA plates were coated with a monoclonal anti-NGF
antibody diluted in carbonate coating buffer (pH 9.7) and
incubated overnight at 4 °C. Plates were then blocked using 1×
blocking buffer (200 μl/well) for 1 h at 20 °C. Following
incubation, NGF standards (0–100 pg/well) or diluted medium
(100 μl) were added to plates and incubated for 6 h at 20 °C.
After washes, plates were incubated with a monoclonal rat
anti-NGF antibody overnight at 4 °C. After a second round of
washes, the plate was incubated with horseradish peroxidase-
conjugated anti-rat antibody (1:4000) for 2 h at 20 °C. Plates
were again washed and incubated with enzyme substrate (TMB
One solution, Promega) for 15 min at 20 °C. The enzyme reaction
was stopped by adding 1 N HCl and the absorbance was
measured at 450 nm by a microplate ELISA reader (Zenyth
3100 ELISA reader or LambdaE, MWG). Sample values were
calculated from a standard curve in the linear range. The
detection limit was 10 pg/ml.
2.16. Searchlight multiplex ELISA
The detection of inflammatory proteins (monocyte chemo-
tactic protein-1, MCP-1; macrophage inflammatory protein-2,
MIP-2; tumor necrosis factor-α, TNFα; interleukin-1β, IL-1β,)
was performed using the Thermo Scientific SearchLight Protein
Array Technology (THP Medical Products, Vienna) according to
themanufacture's recommendations (Bio-Rad) and as previous-
ly described by us (Hohsfield and Humpel, 2010). The lumines-
cent signal was detected using a compatible CCD imaging and
analysis system measuring absorbance at 450 nm. The concen-
tration of each sample was quantified by comparing the spot
intensities with the corresponding standard curves calculated
from the standard sample results using the SearchLight Array
Analyst Software. Integrated density valueswere proportional to
the concentrations of bound proteins. Standard curves, raw data
and final pg/ml concentrations for each analyte and each sample
were reviewed in the array software and exported to Microsoft
Excel Software for further statistical analysis. Sample valueswere
calculated from the standard curve in a linear range.
2.17. Quantitative analysis and statistics
All counts were based on individual sections and show the
total number of neurons per slice. Thenumber ofmicroscopically
detectable immunoreactive ChAT-positive neurons was countedin each whole slice and visualized under the 40× objective by
a blind observer. Multistatistical analysis (KaleidaGraph) was
obtained by one-way ANOVA with Fisher LSD post hoc test,
comparing controls against respective treatments in which
p b 0.05 represents statistical significance.
3. Results
3.1. Evaluation and optimization of primary rat monocyte
gene transfection
We were interested in identifying the most efficient
transfection method for generating NGF-secreting primary rat
monocytes. Each system was optimized and evaluated for
reproducibility and functional gene expression (NGF secretion).
Unfortunately, no NGF secretion was observed in primary
monocytes transfected by electroporation, Effectene or FuGene
(even following extensive optimization) (Table 1). Note that
Table 1 only displays NGF secretion under optimized conditions.
Refer to Methods section for all transfection conditions tested.
Although the transfection conditions tested within each method
were not always equivalent (i.e. DNA concentration) to other
methods tested, this was not the reason for different efficiencies
between systems. DNA input was determined in accordance
with the recommended method levels and thus different
concentrations were needed to optimize each method. When
primary rat monocytes were transfected using nucleofection,
monocytes secreted 0.8 ±0.2 ng/ml NGF per 24 h per 1 million
cells under optimized conditions (determined after many
attempts at varying transfection conditions, see Table 1).
Approximately 10–30% of nucleofected monocytes were
transfected with the pmaxGFP vector (data not shown).
However, monocyte nucleofection reproducibility was low
(21%). Cell viability was also relatively low in nucleofected cells,
where approximately 89%were annexin-V-positive and approx-
imately 51% PI-positive (Fig. 1D–F). Although many attempts
weremade to enhance reproducibility and determine the factors
responsible (i.e. optimizing monocyte isolation/purification,
plasmid purification, plasmid concentration, number of mono-
cytes transfected, presence or absence of recovery periods,
addition of growth factors, incubation time), only 13 out of 62
nucleofections were successful (i.e. produced > 0.1 ng/ml
NGF) (Table 1). We also tested the use of different vector and
promoter systems (i.e. pcDNA3.1-NGF) aswell as nucleofection
programs with no observable improvements.
3.2. Evaluation of primary rat monocyte lentiviral transduction
After our unsuccessful attempts at generating a reproduc-
ible and efficient transfection system for primary rat mono-
cytes, we explored the transfection potential of lentiviral
vectors. HeLa cells were used as a positive control for lentiviral
transductions. They produced 19.5 ± 1.6 and14.5 ± 1.4 ng/ml
NGFwith 100% reproducibility using lentiviral vectors using the
promoters bA and SFFV, respectively (Table 2). Forty-eight
hours after initial infection with vectors pHR-bA-NGF and
pHR-SFFV-NGF, NGF secretionwasmeasured at 15.6 ± 2.5 and
9.1 ± 2.6 ng/ml NGF per 1 million cells, respectively (Table 2).
Although cell cytotoxicity was high at medium collection, the
number of surviving monocytes produced high levels of NGF
with an 86-100% success rate (Table 2).
Table 1
Evaluation of different NGF transfection or transfer methods in primary rat monocytes.
Cell
type
Transfection
method
NGF secretion
[ng/ml × 24 h ×
106 cells]
Set-up Remarks
pA Electroporation 1.9 ± 0.3 (4) 500 V, 1 pulse, 1000 μs, gap width 2, 10 μg DNA,
glia medium (5 μg works as well, but not better)
100% electroporations successful
Consistent NGF transfection method
pA Effectene 31.2 ± 7.8 (12) 2 × 104–2 × 105 cell seeding, 1:10 DNA/Effectene ratio,
0.2 μg DNA, glia medium, 48 h incubation best
86% transfections successful (n = 14)
pA Nucleofection 24.2 ± 6.4 (8) 5 μg DNA (EtOH ppt), T-20 program, glia medium, Amaxa
Rat Astrocyte kit (1 μg DNA tested 1×, similar results)
100% nucleofections successful
pM Electroporation nd (9) 500 V, 1–80 pulses, 50–1000 μs, 1–20 μg DNA 0% electroporations successful
pM Effectene nd (4) 1 μg, 1 × 106 cells (tried 0.2 μg and lower cell population,
but not better), glia medium, 24 h incubation
0% transfections successful
NGF levels so low further testing abandoned
More optimization needed
pM FuGene HD nd (9) 105 cell seeding into 24-well, 0.2–2 μg DNA, 1.7–5 μl
FuGene, Amaxa medium, 6–8 h recovery or no recovery,
24–72 h incubation
0% Fugene transfections successful
pM Nucleofection 0.8 ± 0.2 (13) 2 × 106 cells into 4 collagen coated 4-well or 1 6-well,
Y-001 program, Amaxa medium, 1 μg DNA
(ppt +/−cut), Amaxa Human Monocyte kit
21% nucleofections successful (n = 62)
Extremely inconsistent results
(tested multiple conditions: plasmid purification,
pM purification (Pluriselect), multi pulse, DNA
concentration, pM amount, recovery, growth
factors, different collection methods, different
incubation conditions)
pM Nucleofection nd (6) same as above except different vector (pcDNA3.1-ratNGF) 0% nucleofections successful
pM Bioporter 0.6 ± 0.2 (10) 2.5 × 106 cells, 100 ng NGF, 1–3 h rotating incubation,
3 x 1 ml Optimem washes, Amaxa medium
100% Bioporter deliveries successful
High background, but seems to be good working
method for NGF delivery
Following isolation, primary rat monocytes (pM) were immediately transfected as stated above. Cells were transfected with the pEF-NGF vector unless otherwise
indicated. Following transfection, cells were incubated for 24 h. After incubation, the supernatant was collected and frozen for further analysis. NGF secretion was
measured by NGF ELISA. The experimental set-up is given and indicates all variables tested in attempts to optimize transfection. When only one variable is given,
this indicates that the variable was successful in more effective transfection. Values = mean ± SEM ng/ml of NGF secreted per 1 × 106 monocytes per 24 h. NGF
secretion is corrected for background (n indicates number of replicates under optimized conditions). pEF-(−) vector or pEF-NGF vector without pulse/
transfection reagent served as negative controls. Primary astrocytes (pA) were used as a positive control. Percentage of transfection success refers to transfections
that produced > 0.1 ng/ml NGF under optimized conditions.
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Bioporter
Although NGF secretion by lentiviral transduction was high,
we were still interested in developing a reproducible and non-
viralmethod to generate NGF-secreting primary ratmonocytes.
In this case, we investigated the loading potential of Bioporter, a
protein delivery system. In this study, we demonstrated that
Bioporter delivers recombinant NGF to primary rat monocytes
with a 100% success rate and results in 0.6 ± 0.2 ng/ml of NGF
secretion per 24 h per 1 million cells (Table 1). This method
was comparable to nucleofection in terms of secretion levels,
however, demonstrated a marked improvement in reproduc-
ibility. Bioporter-loaded monocytes also showed a higher cell
viability compared to nucleofected monocytes. Approximately
25% of Bioporter-treated monocytes were annexin V-positive
and approximately 8% were PI-positive (Fig. 1G-I). By immu-
nohistochemistry methods we observed strong NGF immuno-
reactivity in 58 ± 3 (n = 10) % of all DAPI-positive cells
(Fig. 2B). We also observed two distinct staining phenotypes:
a perinuclear staining (33 ± 4 (n = 10) % of all cells; Fig. 2B
and C) and an intracellular/cytoplasmic staining (26 ± 3 (n =
10) % of all cells; Fig. 2B and D). In addition to NGF staining, we
also evaluated these cells for ED1, a common rat monocyte
marker (Fig. 2A), and observed no change in cell phenotype
following Bioporter protein loading. Previous investigation has
shown that Bioporter-loaded monocytes secrete bioactive and
nontoxic NGF (Böttger et al., 2010).3.4. Evaluation of functional properties in primary rat
monocytes loaded with Bioporter
Since Bioporter demonstrated efficient NGF secretion and
resulted in high reproducibility for generating NGF-secreting
primary monocytes, we were also interested in evaluating the
functional properties of these cells. Monocytes transduced by
lentiviral infection were not evaluated functionally. Ultimately,
we wish to pursue studies in an in vivo setting where side
effects from viral vectors still pose potential problems. In
previous experiments, we demonstrated that NGF secretion
from Bioporter-loaded monocytes significantly enhances the
number of cholinergic neurons in organotypic brain slices
(Böttger et al., 2010). However, it still remains unclear whether
these cells maintain proper functioning (i.e. differentiation and
phagocytosis of potentially toxic agents). After 2.5 h exposure
with the peptide, Biporter-loaded cells appeared to take up or
phagocytose FITC-Aβ1–42, as seen by fluorescent cytoplasmic
staining of cells (Fig. 3D–F). We also stained these cells for ED1,
a knownmarker for ratmonocytes/macrophages, andevaluated
the cells for typical macrophage morphology after cultivation
for two days in the presence of M-CSF(Fig. 3A). Monocytes
incubated without M-CSF maintained their typical small and
roundmorphology, whereas, monocytes incubated with M-CSF
exhibited signs of differentiation as seen by an increase in
cytoplasmic volume and the appearance of processes (Fig. 3B
and C). Bioporter-loaded monocytes were also tested for
effective NGF and cytokine secretion at various time intervals.
Fig. 1. Cell viability of primary rat monocytes following transfection and transduction. FACS analysis was performed on monocytes immediately following
isolation (A–C), nucleofection with the NGF expression vector (D–F), or Bioporter delivery with recombinant NGF (G–I). Cell viability was determined by
evaluating the number of necrotic and apoptotic cells using annexin V (B,E,H) and propidium iodide (PI; C,F,I) staining, respectively.
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time-dependent fashion following Bioporter treatment. Expo-
sure to rat Aβ1-42 did not stimulate enhanced cytokine secretion
(Table 3).
4. Discussion
This present study demonstrates the continued difficulty
of transfecting primary rat monocytes, however, providesevidence that lentiviral vectors and protein delivery systems
may prove more effective at generating functional protein
production in these cells.
Although many methods of gene transfer have been
developed for effective genetic modification of mammalian
cells, the engineering and maintenance of monocytic cells has
proven difficult. In the present study, we were unable to
observe effective transfection of primary rat monocytes using
lipid-mediated transfection, electroporation or nucleofection,
Table 2
Evaluation of lentiviral transduction in primary rat monocytes.
Cell
type
Vector NGF secretion
[ng/ml × 106 cells]
Remarks
HeLa pHR-bA-NGF 19.5 ± 1.6 (13)° 100% infections successful
pHR-SFFV-NGF 14.5 ± 1.4 (13)° 100% infections successful
pM pHR-bA-NGF 15.6 ± 2.5 (15) 100% infections successful
pHR-SFFV-NGF 9.1 ± 2.6 (15) 86% infections successful
HeLa - 0.038 ± 0.026 (7) Not applicable
pHR-SFFV-VNP 0.096 ± 0.021 (13) Not applicable
pM – 0.018 ± 0.018 (6) Not applicable
pHR-SFFV-VNP 0.124 ± 0.029 (11) Not applicable
Following isolation, primary rat monocytes were seeded onto a 24-well plate
(0.5 × 106/well) in medium containing antibiotics/antimycotics. At time of
infection,HeLa cellswere75% confluent. Supernatants containing viral particles
were added to the cells and incubated for 24 h. After infection, cells were
washed and new medium was added. Supernatants were then collected after
24 h, 48 h after initial infection, and frozen at −80 °C. NGF secretion was
measured by NGF ELISA. Values = mean ± SEM ng/ml of NGF secreted by
1 × 106 monocytes or °confluent HeLa cells. NGF secretion is corrected for
background (n indicates number of separate wells infected from four
independent experiments). Under Remarks, percentage of infection success
refers to infections that produced > 0.1 ng/ml NGF, whichwere not applicable
for negative controls. HeLa cells were used as a positive control. pHR-SFFV-VNP
expresses a yellow fluorescent protein and was used as a negative control.
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(data not shown). Primary monocytes do not proliferate and
thus it is not surprising that transfection methods that rely on
cell division (i.e. lipid-mediated transfection) have proven
unsuccessful. Thus, recent investigations have turned toFig. 2. Immunohistochemical evaluation of NGF in primary rat monocytes loaded us
(A) or anti-NGF following Bioporter NGF delivery (B–D). Fig. 2A shows that the m
Bioporter-loaded monocytes display a strong NGF-like immunoreactivity that, upo
cytoplasmic space of the monocyte or concentrated near the nucleus (perinuclear)
Scale bar = 30 μm (A), ~7 μm (B), or ~3 μm (C–E).electroporation and nucleofection in order to develop more
efficient nonviral DNA delivery methods for primary cells.
Although advances have been made in primary human mono-
cytes (Bhattacharjee et al., 2008), the nonviral transfection of
primary animal monocytes remains difficult. In line with our
findings, Herold et al. (2006) have reported that electropora-
tion and lipid-mediated transfection were unsuccessful in
transfecting primary rabbit monocytes. Although others have
indicated that transfection efficiencies over 70% can be
achieved in monocytes using Nucleofector technology, most
of these high transfection efficiencies have been performed
using immortal monocytic cell lines rather than primary cells
(Martinet et al., 2003; Schnoor et al., 2009). Recently, others
have demonstrated the successful transfection of mRNA into
primary murine and human monocytes using mouse macro-
phage Nucleofector and Human Monocyte Nucleofector kits,
respectively (Zimmermannet al., 2012). Although ourmethods
(specifically the kit used) are similar to the published study,
our unsuccessful attempts could illustrate the need for a
cell-type specific Nucleofector kit, optimized for primary rat
monocytes, in order to achieve effective transfection. It could
also be possible that mRNA transfection is more potent for
primary monocyte nucleofections. Despite exhaustive optimi-
zation attempts, classical transfectionmethods (i.e. lipid-based
reagents, electroporation, and nucleofection) were unable to
generate stable NGF expression in primary rat monocytes.
Although nucleofection generated some NGF expression in
monocytes (0.8 ± 0.2 ng/ml NGF per 24 h per 1 million cells),
reproducibility was highly variable (21% successful). Even aftering Bioporter. Monocytes were stained for the monocyte specific marker ED1
ajority of primary monocytes are ED1-positive. Fig. 2B demonstrates that
n confocal microscopy evaluation, is incorporated either in the intracellular/
(C–E). Fig. 2E displays a phase contrast image of the cell captured in Fig. 2D.
Fig. 3. Evaluation of functional properties in primary rat monocytes loaded with Bioporter. Monocytes were isolated as usual and cultured for two days in the
absence (A,B) or presence of M-CSF (B,C,E,F). Phagocytosis was evaluated by exposure of FITC-Aβ1–42 for 2.5 h and subsequent visualization under fluorescence
microscope. Intermediate differentiation was evaluated after staining cells with ED1 (A–C). Monocytes cultured without M-CSF maintain their typical small and
round morphology (A). Cells cultured with M-CSF show processes (B) and increased cytoplasmic volume and granularity (C,E,F). Scale bar ~10 μm.
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(i.e. plasmid purity, cell purity, various incubation and culture
conditions, etc.), wewere unable to achieve better reproducible
results. Since our interest is to later administer NGF-secreting
monocytes in vivo, we concluded that this method would not
serve as an attractive method for future experiments.
In this study, we demonstrated that lentiviral vectors and
Bioporter were the most efficient methods for generating
NGF-secreting monocytes. Others have also reported success
using viral transduction methods in these cells. Herold et al.
(2006) demonstrated that adenoviral infection transduced
approximately 95% of primary monocytes and Mordelet et al.
(2002) demonstrated the success and efficiency of lentiviral
transduction for monocyte/macrophage gene delivery in rats.
In this study, monocytes transduced with lentiviral vector
pHR-ba-NGF or pHR-SFFV-NGF produced 15.6 ± 2.5 or 9.1 ±
2.6 ng/ml per 1 million cells, respectively. Both exhibited high
reproducibility at 100% and 86%, respectively. Thus, our data isTable 3
Evaluation of NGF and cytokine secretion following Bioporter transduction and β-a
Condition Time NGF MCP-1
pM-NGF 0.2 70 ± 32 (6) 11 ± 4 (6)
3 202 ± 92 (6) 206 ± 83 (6)
24 473 ± 140 (6) 1658 ± 543 (6
pM-NGF + Aβ 0.2 53 ± 29 (6) 15 ± 10 (6)
3 289 ± 92 (6) 163 ± 71 (6)
24 415 ± 106 (6) 1354 ± 572 (6
Following isolation, primary rat monocytes (pM) were transduced with recombinan
to the culture medium and cell were incubated at 37 °C. Supernatant was collected a
secretion by Searchlight Multiplex ELISA. Values = mean ± SEM pg/ml of NGF
background (n indicates number of replicates). Culture medium served as negativein line with others supporting the use of viral transduction for
successful DNA delivery to primary monocytes.
Since the use of lentiviral vectors still remains controversial
due their immunogenicity properties andwe ultimately plan on
using these cells for in vivo studies, we also investigated
Bioporter as a nonviral approach for generating NGF-secreting
monocytes. Bioporter is a protein delivery system that relies on
lipid complexes to translocate proteins into target cells.
Previous investigations have established that this system can
effectively deliver functional recombinant proteins to a wide
variety of cell types (Böttger et al., 2010). In the present study,
we demonstrate that Bioporter is an efficient nonviral method
to deliver NGF to primary rat monocytes, in which monocytes
secrete 0.6 ± 0.2 ng/ml per 24 h per 1 million cellswith a 100%
rate of reproducibility, 75% viability, and 58 ± 3% efficiency as
seen by immunohistochemical evaluation. Here, we show that
NGF is effectively incorporated into monocytes. Following
confocalmicroscopy,we observed that NGF stainingwasmostlymyloid (Aβ) addition.
MIP-2 TNF-α IL-1β
4 ± 1 (6) nd (6) nd (6)
187 ± 70 (6) 184 ± 71 (6) nd (6)
) 383 ± 118 (6) 103 ± 25 (6) 33 ± 12 (6)
4 ± 3 (6) nd (6) nd (6)
171 ± 78 (6) 138 ± 61 (6) nd (6)
) 324 ± 124 (6) 82 ± 25 (6) 20 ± 8 (6)
t NGF using Bioporter. Following transduction, 10 μg/ml rat Aβ1–42 was added
fter 0.2, 3, and 24 h. NGF secretion was measured by NGF ELISA and cytokine
or cytokine secreted per 1 × 106 monocytes. Secretion is corrected for
controls.
Fig. 4. The effects of conditioned medium from NGF-loaded monocytes on the survival of cholinergic neurons. Organotypic nuclus basalis of Meynert brain slices
were incubated with conditioned medium from primary monocytes loaded with Bioporter alone (A) or NGF (B). An enhanced number of ChAT (choline
acetyltransferase)-positive cholinergic neurons survived when incubated with medium from NGF-loaded cells. Fig. 4C shows the number of cholinergic neurons
in organotypic brain slices incubated for 2 weeks without NGF (minus), with 10 ng/ml recombinant NGF (NGF 10), with conditioned medium from cells loaded
with Bioporter alone (pM-(−)) or conditioned medium from cells loaded with Bioporter containing NGF (pM-NGF). Values represent mean ± SEM
ChAT + neurons/slice (C). In order to calculate ng NGF/mg protein, brain slice extracts were collected and measured for NGF by NGF ELISA (ng/ml NGF) and then
divided by their total protein (mg protein) determined by Bradford protein assay. Statistical analysis was performed by one-way ANOVA with LSD post hoc test
(*** p b 0.001, * p b 0.05). Scale bar = 30 μm (A & B). Values were obtained and modified from Böttger et al., 2010.
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some cells are quicker at NGF uptake (perinuclear staining)
compared to other cells (cytoplasmic staining). Sincewedid not
perform further staining of lysosomes or endosomes, we cannot
identify the exact location of NGF. However, these two different
stainings patterns could indicate that these cells exhibit
differential abilities at taking up and secreting NGF. However,
further analysis is needed to determine to what extent this
occurs and how it differs within each group.
Most importantly, however, these cells secrete bioactive
NGF. We have previously demonstrated that the production
of NGF in primary rat monocytes enhances the number of
cholinergic neurons in organotypic brain slices (Fig. 4). This is
important to evaluate since proNGF, the uncleaved precursor
of NGF, has been implicated in neuronal cell death (Fortress
et al., 2011). Our data indicate that conditionedmedium from
NGF-secreting cells can promote the survival of cholinergic
neurons, as measured by choline acetyltransferase (ChAT)-
positive neurons.
In addition, we investigated the functional capabilities of
these cells following Bioporter treatment. These analyses were
only carried out in Bioporter-transduced monocytes and not in
lentiviral-transduced cells. A recent study has published that
haematopoietic stem cells transduced by lentiviral vector do not
present any alterations in monocytic differentiation and func-
tion (Magga et al., 2012). However, lentiviral modification still
poses potential problematic side effects, such as high viral titers
and immunogenic effects that we wish to avoid in our future in
vivo studies. Here, we show that Bioporter-loaded monocytes
can phagocytose Aβ and appear to develop morphological
changes (i.e. larger cytoplasm, appearance of processes)
indicative of differentiation. Although seven days are needed
for monocytes to become fully differentiated into macrophages
in culture, we were only interested in their short-term
functional capabilities. This is due to the fact that these cells
exhibit rather short life-spans once in circulation in vivo.Fig. 5. Therapeutic potential of transmigrating monocytes. We propose that periphe
via blood–brain barrier (BBB) activation/disruption. Subsequently, these cells are rec
to disease lesion sites (i.e. Aβ plaque deposition) where they can phagocytose Aβ,This present work extends our earlier studies of the
potential therapeutic use of peripheral monocytes for the
delivery of NGF to the brain (Zassler and Humpel, 2006;
Böttger et al., 2010). Despite extensive evidence supporting
the therapeutic potency of NGF (Tuszynski et al., 2005;
Nagahara et al., 2009), its use in the treatment of CNS
disorders has been limited due to its inability to penetrate
the blood–brain barrier (BBB) and the adverse and intolerable
side effects (e.g. nociceptor activation) that appear upon
broad NGF distribution (Covaceuszach et al., 2009). Previous
investigations have taught us that in order to develop an
effective NGF delivery system, it should adhere to the
following criteria: 1) supply a sufficient quantity of NGF to
effectively stimulate degenerating neurons, 2) provide con-
tinuous delivery of NGF, 3) restrict NGF distribution to lesion
sites, and 4) in regards to an ever growing AD population,
provide efficient, reproducible, and non-invasive application.
In order to address these concerns, we propose the use of
peripheral monocytes as NGF delivery vehicles to the AD brain.
We and others have shown that Aβ deposits can stimulate
monocyte recruitment and infiltration into the brain (Fiala et al.,
1998; Giri et al., 2000; Humpel, 2008). Furthermore, recent
studies have shown that bonemarrow-derived or blood-derived
monocytic cells are recruited to the diseased AD brain and play
an important role in the clearance of Aβ deposits and plaques (El
Khoury et al., 2007; Gate et al., 2010; Lebson et al., 2010). This
selective transmigration to amyloid plaques confers a gross
advantage for the use of these cells as therapeutic delivery
vehicles to the AD brain (Malm et al., 2010; Schwartz and
Shechter, 2010). We hypothesize that following BBB insult (e.g.
activation or breakdown) or stimuli from disease-associated
lesion sites (i.e. Aβ plaque), monocytes can transmigrate across
the BBB and enter the diseased AD brain (Fig. 5). Monocytes are
then attracted to the lesion site by a chemotactic gradient (e.g.
monocyte chemotactic protein-1 (MCP-1/CCL2))where they can
secrete NGF to support the survival of degenerating cholinergicral monocytes carrying NGF can gain access to the Alzheimer's disease brain
ruited by chemokines (e.g. monocyte chemotactic protein-1 (MCP-1/CCL-2))
secrete NGF, and ultimately help counteract neurodegeneration.
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into macrophages and phagocytosing Aβ (Fig. 5).
Although a number of recent studies have reported on the
therapeutic potential of monocytes in AD (Lebson et al., 2010),
the role of these cells in contributing to further inflammatory
activity and disease aggrevation should still be considered.
Their response to neurodegeneration can be beneficial, but
ultimately become detrimental once dysregulated and persis-
tent (Shechter and Schwartz, 2013). Other hurdles will include
generating large populations of healthy functioningmonocytes
since these cells are short-lived, exhibit limited numbers in
vivo, and are ineffective at Aβ phagocytosis in Alzheimer's
patients (Fiala et al., 2005).
In the rat brain, physiological levels of NGF have been
reported at 1.01 ng/g tissue and 0.2 ng/g tissue in the hippo-
campus and cortex, respectively (Whittemore et al., 1986). In
mice, reducingNGF brain levels from13–17 ng/mg inwildtype
animals to 6 ng/mg in transgenic anti-NGF animals results in
AD-like neurodegeneration (Capsoni et al., 2010).
The mechanisms of NGF secretion has been studied exten-
sively in hippocampal neurons and a previous investigation has
also shown that monocytes can produce, store, and release NGF
(Rost et al., 2005). However, the cellular pathway involved in its
release has not been fully characterized. Themainmechanism of
Bioporter-loaded protein secretion is through macropinoctosis,
which can often lead to remaining protein left trapped in
endosomal vesicles (Yamaguchi et al., 2011). Here, we show that
primarymonocytes loadedwith NGF using Bioporter can secrete
NGF in a time-dependent manner over 24 h. This is also true for
endogenous cytokines indicating that protein secretion is active
rather than a result of proteolytic degradation, however, further
investigation is required. On the other hand, whether or not
monocyte cell death does indeed occur, the more important
point is that NGF is released from our cells. Other studies have
reported that Aβ1–42 significantly elevates the release of
inflammatory cytokines in monocytes (Fiala et al., 1998).
Differences in our findings may be due to culturing variations, a
longer incubation period and higher doses of Aβ. Our future
studies will involve administrating Bioporter-NGF-loaded pri-
mary monocytes and observing whether these cells can deliver
therapeutically relevant levels of NGF as well as help reduce
β-amyloid deposition and cholinergic neurodegeneration.
5. Conclusion
The present study illustrates that primary rat monocytes
can be efficiently loaded with NGF using lentivirus vectors or
Bioporter. It further shows that NGF secreted from these cells
is bioactive and that Bioporter does not disrupt monocyte
functional properties. These findings provide insights into the
use of peripheral monocytes as brain delivery vehicles for NGF
and this approach may have implications in the future for the
treatment of AD and other neurodegenerative diseases.
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